| Title |
State |
Investigator/Sponsoring Organization |
Evaluation for NCI Surgery Branch Clinical Research Protocols
NCT ID: NCT00001823
|
Maryland
|
National Cancer Institute (NCI) |
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
NCT ID: NCT00579514
|
New York
|
Memorial Sloan Kettering Cancer Center |
Prophylactic Cranial Irradiation (PCI) for Patients With Small Cell Carcinoma of the Urothelium
NCT ID: NCT00756639
|
Texas
|
M.D. Anderson Cancer Center |
Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach
NCT ID: NCT00848289
|
Texas
|
M.D. Anderson Cancer Center |
Non-Invasive Assays for the Detection of Urothelial Cancer of the Bladder and Kidney
NCT ID: NCT00872495
|
Massachusetts
|
Lahey Clinic |
Familial and Atypical Urothelial Cancer Registry
NCT ID: NCT00902590
|
Multi-State Trial
|
Memorial Sloan Kettering Cancer Center |
Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
NCT ID: NCT00978250
|
Multi-State Trial
|
National Cancer Institute (NCI) |
PORCH: A Registry of Prospective Outcomes of Radical Cystectomy With or Without Chemotherapy
NCT ID: NCT01776138
|
North Carolina
|
UNC Lineberger Comprehensive Cancer Center |
Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy
NCT ID: NCT01050504
|
Washington
|
University of Washington |
Selective Bladder Preserving Treatment by Radiation Therapy Concurrent With Radiosensitizing Chemot...
NCT ID: NCT00981656
|
Multi-State Trial
|
Radiation Therapy Oncology Group |
Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Perfo...
NCT ID: NCT01224665
|
Multi-State Trial
|
Southwest Oncology Group |
Study of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tra...
NCT ID: NCT01261728
|
Multi-State Trial
|
Memorial Sloan Kettering Cancer Center |
Dose Escalation Study of MGA271 in Refractory Cancer
NCT ID: NCT01391143
|
Multi-State Trial
|
MacroGenics |
Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
NCT ID: NCT01631552
|
Multi-State Trial
|
Immunomedics, Inc. |
PK Button Vaporization Electrode for Treatment of Bladder Tumors
NCT ID: NCT01567462
|
Georgia
|
Emory University |
Randomized Placebo-Controlled Clinical Trial of Genistein in Reducing the Toxicity and Improving the...
NCT ID: NCT01489813
|
Georgia
|
Emory University |
Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumor...
NCT ID: NCT01638533
|
Multi-State Trial
|
National Cancer Institute (NCI) |
Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Aveluma...
NCT ID: NCT01772004
|
Multi-State Trial
|
EMD Serono |
LCCC 1209: Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance I...
NCT ID: NCT01655745
|
North Carolina
|
UNC Lineberger Comprehensive Cancer Center |
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
NCT ID: NCT01772771
|
Texas
|
M.D. Anderson Cancer Center |
Trial of Prehabilitation in Vulnerable Patients Undergoing Cystectomy for Bladder Cancer
NCT ID: NCT01840137
|
Michigan
|
University of Michigan |
Phase 2 Study Exploring the Efficacy and Safety of Neratinib Therapy in Patients With Solid Tumors ...
NCT ID: NCT01953926
|
Multi-State Trial
|
Puma Biotechnology, Inc. |
A Randomized Trial of a Family Caregiver Palliative Care Intervention
NCT ID: NCT01846520
|
California
|
City of Hope Medical Center |
Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tol...
NCT ID: NCT01976741
|
Multi-State Trial
|
Bayer |
Study of Adjuvant 3D-Conformal Radiotherapy in High Risk Bladder Cancer
NCT ID: NCT01954173
|
Georgia
|
Emory University |
Study of Albumin-bound Rapamycin Nanoparticles (Nab-rapamycin, ABI-009) in the Treatment of BCG Refr...
NCT ID: NCT02009332
|
New York
|
Aadi, LLC |
Immunopheotype of Locally Advanced Rectal Adenocarcinoma and Its Correlation With the Efficacy of Ne...
NCT ID: NCT02017509
|
Oregon
|
Providence Health & Services |
Integrated Cancer Repository for Cancer Research
NCT ID: NCT02012699
|
Multi-State Trial
|
University of Nebraska |
Intravenous CAVATAK™ (Coxsackievirus A21, CVA21) Alone and in Combination With Pembrolizumab in Pati...
NCT ID: NCT02043665
|
Multi-State Trial
|
Viralytics |
Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
NCT ID: NCT02080650
|
North Carolina
|
Duke University |
Biomarker Identification for Bladder Cancer Patients
NCT ID: NCT02053662
|
Ohio
|
Ohio State University Comprehensive Cancer Center |
Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Metastases in Genitourinary (...
NCT ID: NCT02141490
|
Maryland
|
National Cancer Institute (NCI) |
Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Com...
NCT ID: NCT02145390
|
Florida
|
University of Miami |
Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle ...
NCT ID: NCT02138734
|
Multi-State Trial
|
Altor Bioscience Corporation |
Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients U...
NCT ID: NCT02145871
|
New York
|
Memorial Sloan Kettering Cancer Center |
Chemoprevention Trial of Weekly Erlotinib Before Bladder Cancer Surgery
NCT ID: NCT02169284
|
Multi-State Trial
|
National Cancer Institute (NCI) |
Bacillus Calmette-Guerin (BCG) Given in Combination With PANVAC[TM] Versus BCG Given Alone in Adults...
NCT ID: NCT02015104
|
Maryland
|
National Cancer Institute (NCI) |
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment of BCG-Refractory Non-mu...
NCT ID: NCT02202772
|
New York
|
James M. McKiernan |
Prospective Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to C...
NCT ID: NCT02170181
|
Texas
|
University of Texas Southwestern Medical Center |
Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Inv...
NCT ID: NCT02177695
|
Multi-State Trial
|
Southwest Oncology Group |
Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Ta...
NCT ID: NCT02223052
|
Multi-State Trial
|
Celgene |
Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improv...
NCT ID: NCT02203136
|
Texas
|
M.D. Anderson Cancer Center |
Phase II Trial of Estrogen Receptor Targeted Treatment of Non-Muscle Invasive Bladder Cancer With Ta...
NCT ID: NCT02197897
|
Texas
|
Baylor College of Medicine |
Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or...
NCT ID: NCT02240238
|
Multi-State Trial
|
NanoCarrier Co., Ltd. |
Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts
NCT ID: NCT02246738
|
Pennsylvania
|
Abramson Cancer Center of the University of Pennsylvania |
Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study
NCT ID: NCT02298998
|
Texas
|
The University of Texas Health Science Center at San Antonio |
Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) fo...
NCT ID: NCT02281383
|
Multi-State Trial
|
Memorial Sloan Kettering Cancer Center |
Study of Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
NCT ID: NCT02300610
|
Florida
|
H. Lee Moffitt Cancer Center and Research Institute |
Study of MK-3475 in Combination With BCG for Patients With High Risk Superficial Bladder Cancer
NCT ID: NCT02324582
|
Illinois
|
Southern Illinois University |
Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
NCT ID: NCT02318329
|
Multi-State Trial
|
Five Prime Therapeutics, Inc. |
Randomized Placebo Control Trial of Perioperative Gabapentin to Reduce Total Analgesic Requirements ...
NCT ID: NCT02355886
|
Washington
|
University of Washington |
High Resolution Imaging for Early and Better Detection of Bladder Cancer
NCT ID: NCT02340650
|
Texas
|
The University of Texas Health Science Center, Houston |
Evaluating Local and Regional Immune Responses to Intravesical BCG Administration to Patients With I...
NCT ID: NCT02365207
|
Texas
|
The University of Texas Health Science Center at San Antonio |
A Phase 1, Open-label, Dose Escalation Study Of Pf-04518600 As A Single Agent And In Combination Wit...
NCT ID: NCT02315066
|
Multi-State Trial
|
Pfizer |
Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-...
NCT ID: NCT02365766
|
Multi-State Trial
|
Christopher Hoimes, M.D. |
Care of the Urothelial Cancer Patient and Prospective Collection of Biospecimens From Healthy Volunt...
NCT ID: NCT02379429
|
Maryland
|
National Cancer Institute (NCI) |
Study of B-701 Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment of Locally Advanced or ...
NCT ID: NCT02401542
|
Multi-State Trial
|
BioClin Therapeutics, Inc. |
Determinants of Bladder Cancer Recurrence Study (The DETER Study)
NCT ID: NCT02400944
|
Multi-State Trial
|
Memorial Sloan Kettering Cancer Center |
Study of Ixazomib in Combination With Gemcitabine and Doxorubicin, Followed by a Phase II Extension ...
NCT ID: NCT02420847
|
Texas
|
M.D. Anderson Cancer Center |
Study of a p53MVA Vaccine in Combination With Pembrolizumab
NCT ID: NCT02432963
|
California
|
City of Hope Medical Center |
Feasibility Trial of MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer
NCT ID: NCT02437370
|
California
|
University of California, Davis |
Prevention of Parastomal Hernia Following Radical Cystectomy and Ileal Conduit Using Biologic Mesh: ...
NCT ID: NCT02439060
|
California
|
University of Southern California |
Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metast...
NCT ID: NCT02443324
|
Multi-State Trial
|
Eli Lilly and Company |
Study of Regorafenib for Advanced Urothelial Cancer Following Prior Chemotherapy
NCT ID: NCT02459119
|
Multi-State Trial
|
University of Alabama at Birmingham |
Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects With Non-metastatic Transitional Cell Carcino...
NCT ID: NCT02451423
|
California
|
University of California, San Francisco |
Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscl...
NCT ID: NCT02449239
|
Multi-State Trial
|
Viventia Bio |
Ultrasound and Biomarker Tests of Bladder Cancer Invasiveness
NCT ID: NCT02494635
|
California
|
University of Southern California |
Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi...
NCT ID: NCT02496208
|
Multi-State Trial
|
National Cancer Institute (NCI) |
Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Met...
NCT ID: NCT02500121
|
Multi-State Trial
|
Matthew Galsky |
Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment ...
NCT ID: NCT02546661
|
Multi-State Trial
|
AstraZeneca |
Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax®-TF-ADC) in Patient...
NCT ID: NCT02552121
|
Multi-State Trial
|
Genmab |
Study of LY3076226, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody-Drug Conjugate, in Patien...
NCT ID: NCT02529553
|
Multi-State Trial
|
Eli Lilly and Company |
Study of Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients Wit...
NCT ID: NCT02553642
|
Multi-State Trial
|
Memorial Sloan Kettering Cancer Center |
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without VX-970 in Metastatic Urothelial ...
NCT ID: NCT02567409
|
Multi-State Trial
|
National Cancer Institute (NCI) |
Study of Curcumin and Piperine to Derive a Safe, Optimal Biologic Dose for Ureteral Stent-Induced Sy...
NCT ID: NCT02598726
|
Minnesota
|
Mayo Clinic |
Phase II Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Urothelial Cancer
NCT ID: NCT02560038
|
Texas
|
The University of Texas Health Science Center, Houston |
Study of Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
NCT ID: NCT02612194
|
North Carolina
|
Earle Burgess |
Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination Wi...
NCT ID: NCT02619253
|
Multi-State Trial
|
Roberto Pili |
Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects With High Risk Non-muscle Invas...
NCT ID: NCT02625961
|
Multi-State Trial
|
Merck Sharp & Dohme Corp. |
Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as...
NCT ID: NCT02621151
|
New York
|
New York University School of Medicine |
The Effect of Androgen Deprivation Therapy With Enzalutamide on Bladder Cancer Chemoprevention
NCT ID: NCT02605863
|
New York
|
University of Rochester |
Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-A...
NCT ID: NCT02628535
|
Multi-State Trial
|
MacroGenics |
A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subje...
NCT ID: NCT02632409
|
Multi-State Trial
|
Bristol-Myers Squibb |
Study of Enadenotucirev Combined With PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithel...
NCT ID: NCT02636036
|
Multi-State Trial
|
PsiOxus Therapeutics Ltd |
Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Recep...
NCT ID: NCT02643303
|
New York
|
Ludwig Institute for Cancer Research |
A Pilot Study of a Rapid Access Platform for Investigational Drugs (RAPID) in Advanced Cancers
NCT ID: NCT02646319
|
Arizona
|
Mayo Clinic |
Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers
NCT ID: NCT02648178
|
New Hampshire
|
Dartmouth-Hitchcock Medical Center |
Optional Sub-study to Intraoperative Imaging With ICG Registry
NCT ID: NCT02651246
|
Pennsylvania
|
Abramson Cancer Center of the University of Pennsylvania |
Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystec...
NCT ID: NCT02655081
|
Pennsylvania
|
University of Pittsburgh |
Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incu...
NCT ID: NCT02655822
|
Multi-State Trial
|
Corvus Pharmaceuticals, Inc. |
Study of BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT ID: NCT02657486
|
New York
|
Memorial Sloan Kettering Cancer Center |
Blue Light Cystoscopy With Cysview® Registry
NCT ID: NCT02660645
|
Multi-State Trial
|
Photocure |
A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
NCT ID: NCT02675829
|
New York
|
Memorial Sloan Kettering Cancer Center |
Study of Gemcitabine and Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystec...
NCT ID: NCT02690558
|
North Carolina
|
UNC Lineberger Comprehensive Cancer Center |
A Phase II Trial to Evaluate Pemetrexed Clinical Responses in Relation to Tumor MTAP Gene Status in ...
NCT ID: NCT02693717
|
Texas
|
M.D. Anderson Cancer Center |
Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately A...
NCT ID: NCT02695771
|
Multi-State Trial
|
Spectrum Health Hospitals |
Risk of Bladder Cancer Between Patients With Type 2 Diabetes Exposed to Dapagliflozin and Those Expo...
NCT ID: NCT02695121
|
Multi-State Trial
|
AstraZeneca |
Prospective Randomized Comparison of Robotic Versus Open Radical Cystectomy
NCT ID: NCT02699853
|
California
|
University of Southern California |
Observation Versus Immediate Surgery of Low Risk Bladder Cancer
NCT ID: NCT02700724
|
Tennessee
|
Vanderbilt University |
Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced or Recurrent...
NCT ID: NCT02710396
|
Multi-State Trial
|
Naiyer Rizvi |
Trimodality Bladder Preservation Therapy: Maximal Transurethral Resection Followed by Accelerated Me...
NCT ID: NCT02710734
|
Pennsylvania
|
Fox Chase Cancer Center |
A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-7435) for Met...
NCT ID: NCT02717156
|
California
|
University of Southern California |
The Feasibility of a Diet and Exercise Intervention in Diabetics During Treatment for Non-muscle Inv...
NCT ID: NCT02716623
|
Kansas
|
University of Kansas Medical Center |
Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder
NCT ID: NCT02745301
|
Tennessee
|
Vanderbilt University |
Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Mu...
NCT ID: NCT02722538
|
Multi-State Trial
|
Taris Biomedical LLC |
A Pilot Study to Test Rapid Acquisition of Point of Care Ultrasound for Various Applications
NCT ID: NCT02831556
|
North Carolina
|
Duke University |
Molecular Analysis for Therapy Choice (MATCH)
NCT ID: NCT02465060
|
Multi-State Trial
|
National Cancer Institute (NCI) |
A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers
NCT ID: NCT02767921
|
California
|
University of Southern California |
Study Of Avelumab (msb0010718c) Plus Best Supportive Care Versus Best Supportive Care Alone As A Mai...
NCT ID: NCT02603432
|
Multi-State Trial
|
Pfizer |
Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-Interferon (IFN)/Syn3) Administered I...
NCT ID: NCT02773849
|
Multi-State Trial
|
FKD Therapies Oy |
STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ADMINISTERED WITH OR WITHOUT BACILLE CALMETTE-G...
NCT ID: NCT02792192
|
Multi-State Trial
|
Hoffmann-La Roche |
A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
NCT ID: NCT02788201
|
Maryland
|
National Cancer Institute (NCI) |
Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-...
NCT ID: NCT02808143
|
Illinois
|
Northwestern University |
Study of Atezolizumab (Anti−PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Ch...
NCT ID: NCT02807636
|
Multi-State Trial
|
Hoffmann-La Roche |
Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Pa...
NCT ID: NCT02812420
|
Texas
|
M.D. Anderson Cancer Center |
Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry Optional Sub-Study I: ...
NCT ID: NCT02852252
|
Pennsylvania
|
University of Pennsylvania |
Pilot Study of Celecoxib Combined With Gemcitabine and Cisplatin for Neoadjuvant Treatment of Locali...
NCT ID: NCT02885974
|
Texas
|
Baylor College of Medicine |
Steps to Eliminate Postoperative Problems
NCT ID: NCT02880176
|
Pennsylvania
|
University of Pennsylvania |
Phase II Study of Nanoparticle Albumin-bound Paclitaxel Plus Gemcitabine as First-line Therapy for t...
NCT ID: NCT02887248
|
Multi-State Trial
|
SCRI Development Innovations, LLC |
Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Pati...
NCT ID: NCT02891161
|
Iowa
|
Monika Joshi |
A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malign...
NCT ID: NCT02897375
|
Georgia
|
Emory University |
Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinom...
NCT ID: NCT02897765
|
Multi-State Trial
|
Neon Therapeutics, Inc. |
A Phase 2 Study of Check Point Inhibitor, Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) R...
NCT ID: NCT02901548
|
Florida
|
H. Lee Moffitt Cancer Center and Research Institute |
A Prospective, Randomized Trial of Preventive Mesh Placement at the Time of Radical Cystectomy to Re...
NCT ID: NCT02908061
|
Multi-State Trial
|
Memorial Sloan Kettering Cancer Center |
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
NCT ID: NCT02834013
|
Multi-State Trial
|
National Cancer Institute (NCI) |
Intravenous Lidocaine in the Perioperative Setting and the Effects on Postoperative Pain and Bowel F...
NCT ID: NCT02924480
|
West Virginia
|
CAMC Health System |
Application-based Perioperative Management of the Radical Cystectomy Patient
NCT ID: NCT02942121
|
Kansas
|
University of Kansas Medical Center |
Study of SGN-2FF in Patients With Advanced Solid Tumors
NCT ID: NCT02952989
|
Multi-State Trial
|
Seattle Genetics, Inc. |
Electro-Phage and Colorimetric Aptamer Sensors for Clinical Staging and Monitoring of Bladder Cancer
NCT ID: NCT02957370
|
California
|
University of California, Irvine |
A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Adv...
NCT ID: NCT02964013
|
Texas
|
Merck Sharp & Dohme Corp. |
Assessment of Reliability of Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladd...
NCT ID: NCT02968732
|
Pennsylvania
|
Fox Chase Cancer Center |
Clinical Validation of a Urine-based Assay With Genomic and Epigenomic Markers for Predicting Recurr...
NCT ID: NCT02969109
|
Minnesota
|
Genomic Health®, Inc. |
A Clinical Trial To Evaluate Image-Guided Gynecologic Brachytherapy In The MR Simulator Suite
NCT ID: NCT02993900
|
Maryland
|
Sidney Kimmel Comprehensive Cancer Center |
Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered M...
NCT ID: NCT02989064
|
Multi-State Trial
|
Adaptimmune |
A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin With Atezolizumab (M...
NCT ID: NCT02989584
|
New York
|
Memorial Sloan Kettering Cancer Center |
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combinat...
NCT ID: NCT03022825
|
Multi-State Trial
|
Altor Bioscience Corporation |
Targeting a Genomic Biomarker for PET Imaging and Staging of Urothelial Cancer: A Preliminary Evalua...
NCT ID: NCT03039413
|
Pennsylvania
|
Sidney Kimmel Cancer Center at Thomas Jefferson University |
Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patie...
NCT ID: NCT03023319
|
Ohio
|
Nagla Karim |
Functional Imaging of T-cell Activation With [18F]F-AraG in Bladder Cancer Patients Receiving Neoadj...
NCT ID: NCT03007719
|
California
|
Lawrence Fong |
Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer
NCT ID: NCT03063125
|
Kansas
|
University of Kansas Medical Center |
An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of t...
NCT ID: NCT03047213
|
Multi-State Trial
|
National Cancer Institute (NCI) |
Comparison of Obturator Nerve Blockade and Neuromuscular Blockade for the Prevention of Adductor Spa...
NCT ID: NCT03063255
|
Florida
|
University of Florida |
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell P...
NCT ID: NCT03091660
|
Multi-State Trial
|
Southwest Oncology Group |
Study To Evaluate Dna Methlyation Markers For Detection Of Primary Bladder Cancer In Urine Samples ....
NCT ID: NCT03122964
|
Texas
|
MDx Health |
Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Uro...
NCT ID: NCT03093922
|
Multi-State Trial
|
Memorial Sloan Kettering Cancer Center |
Novel FGFR3 Inhibitor (B-701) Combined With Atezolizumab in Subjects With Locally Advanced or Metast...
NCT ID: NCT03123055
|
Pennsylvania
|
BioClin Therapeutics, Inc. |
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics,...
NCT ID: NCT03125200
|
New York
|
ADC Therapeutics SARL |
Clinical Evaluation of Xpert Bladder Cancer Monitor for Monitoring the Recurrence of Bladder Cancer
NCT ID: NCT03125460
|
Multi-State Trial
|
Cepheid |
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)
NCT ID: NCT03133286
|
California
|
DxTerity Diagnostics |
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity...
NCT ID: NCT03132922
|
Tennessee
|
Adaptimmune |
A Phase 1b, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR...
NCT ID: NCT03138889
|
Multi-State Trial
|
Nektar Therapeutics |
LCCC 1636: Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder C...
NCT ID: NCT03156244
|
North Carolina
|
UNC Lineberger Comprehensive Cancer Center |
A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer
NCT ID: NCT03193515
|
Hawaii
|
University of Hawaii |
A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer
NCT ID: NCT03193528
|
Hawaii
|
University of Hawaii |
St. Judes-Stanford Comprehensive Support Initiative
NCT ID: NCT03154190
|
California
|
Stanford University |
ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
NCT ID: NCT03193541
|
Hawaii
|
University of Hawaii |
Measuring Surgical Recovery After Radical Cystectomy
NCT ID: NCT03193970
|
Multi-State Trial
|
M.D. Anderson Cancer Center |
MDSC Clinical Assay for Cancer Detection and Monitoring in Bladder Carcinoma
NCT ID: NCT02735512
|
California
|
University of Southern California |
A Randomized Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive ...
NCT ID: NCT02753309
|
Texas
|
The University of Texas Health Science Center at San Antonio |
Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in P...
NCT ID: NCT03250832
|
Multi-State Trial
|
Tesaro, Inc. |
Study of Qapzola™ (Apaziquone) as a Chemotherapy Adjuvant to TransUrEthral Resection of Bladder Tumo...
NCT ID: NCT03224182
|
Pennsylvania
|
Spectrum Pharmaceuticals, Inc |
TraceIT TM Hydrogel Tissue Marker for Patients Receiving Definitive Chemoradiation for Bladder Cance...
NCT ID: NCT03125226
|
Washington
|
University of Washington |
Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer
NCT ID: NCT02844816
|
Multi-State Trial
|
National Cancer Institute (NCI) |
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma: A Multice...
NCT ID: NCT02700464
|
Multi-State Trial
|
Nucleix Ltd. |
Phase I-II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting ...
NCT ID: NCT02153905
|
Maryland
|
National Cancer Institute (NCI) |
Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer
NCT ID: NCT02122172
|
Multi-State Trial
|
University of Chicago |
A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel™ on Ablation of Upper Urin...
NCT ID: NCT02793128
|
Multi-State Trial
|
UroGen Pharma Ltd. |
A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery fo...
NCT ID: NCT02412670
|
Multi-State Trial
|
ECOG-ACRIN Cancer Research Group |
Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in Selected Tumor Types Based on Genomic Alterations
NCT ID: NCT02795156
|
Colorado
|
SCRI Development Innovations, LLC |
